Absci Corporation · NASDAQ:ABSI
Absci — Investor Presentation (March 2026)
79 slides from Absci's investor presentation, Mar 24, 2026
Slide 1: Corporate Presentation March 2026
Corporate Presentation March 2026 GENERATIVE AI DRUG CREATION CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED
Slide 2: Disclaimers
Disclaimers F O R W A R D - L O O K I N G S T A T E M E N T S Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to
Slide 3: Leading AI Platform for Creating Antibody-Based Therapeutics
LEADING AI PLATFORM FOR CREATING ANTIBODY-BASED THERAPEUTICS 1. DIFFERENTIATED PIPELINE OF AI-DESIGNED THERAPEUTICS2. From Code to Clinic CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 3 A B S C I | I N T R O o Interdisciplinary Team with 10+ approved drugs a
Slide 4: Industrializing Drug Discovery
Industrializing Drug Discovery INCREASING ‘SHOTS-ON GOAL’ WITH FASTER AND CAPITAL EFFICIENT DISCOVERY $10-15mil (Absci) $50-100mil (Large Pharma) 24 Months (Absci) 5-6 years (Large Pharma) C A P IT A L IN V E S T M E N T D IS C O V E R Y T IM E L IN E DELIVERING 3 CLINICAL- STAGE PROGRAMS TO DATE 1
Slide 5: Leadership in AI de novo design of antibody-based therapeutics
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 5 D E N O V O D E S I G N Leadership in AI de novo design of antibody-based therapeutics De Novo Antibody DesignAI Lead Optimization De novo antibody design model creates epitope-specific binders given a target s
Slide 6: We use AI to create novel & differentiated therapeutics
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 6 D E N O V O D E S I G N We use AI to create novel & differentiated therapeutics ENABLING FEATURES: MULTI-VALENCY, pH-DEPENDENT BINDING ABILITY TO ADDRESS DIFFICULT TARGET CLASSES, E.G. GPCRS EPITOPE-SPECIFIC DE
Slide 7: Drug Creation Platform
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 7 D R U G C R E A T I O N P L A T F O R M Leveraging AI throughout the end-to-end drug discovery process TARGET SELECTION AI-GUIDED LEAD OPTIMIZATION AI-GUIDED DRUG CREATION AI reverse immunology target discovery
Slide 8: Progress in AI de novo antibody design
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 8 Since publishing the first work in AI de novo antibody design, Absci has continued to rapidly progress and lead the field 2024 2025 20262022 de novo Model v1 Absci was the first to design and validate novel ant
Slide 9: Platform case studies
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 9 C A S E S T U D I E S Platform case studies AI Lead Optimization De Novo Antibody Design Goal: Create universally neutralizing HIV antibody by binding conserved epitope within “Caldera” region of HIV gp120 Absc
Slide 10: Multilingual team with expertise in AI and drug creation
”Multilingual” team with expertise in AI and drug creation CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 10 T E A M Sean McClain Founder, CEO & Board Director Zach Jonasson, PhD Chief Financial Officer & Chief Business Officer Amir Shanehsazzadeh SVP, Chief
Slide 11: Absci at a Glance
11 140 E M P L O Y E E S Biologics drug discovery expertise from: “Multi-lingual” AI + Drug Discovery expertise AI team drawing on experience from tech leaders: 77,000 S Q U A R E F E E T o State-of-the-art wet and dry lab in Vancouver WA o Absci AI Research (AAIR) lab in NYC o Innovation Centre in
Slide 12: Pipeline
*or equivalent ex-US filing C L I N I C A L S T A G E P I P E L I N E R E A D Y F O R P A R T N E R I N G N E X T - G E N P I P E L I N E COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 12 P I P E L I N E T H E R A P E U T I C A R E A T A R G E T I D L E A D I D C A N D I D A T E I D I N D
Slide 13: Track record of industry-leading partnerships
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 13 P A R T N E R S H I P S Track record of industry-leading partnerships AI Drug Creation™ Data & Compute Trademarks, service marks or trade names referred to herein are the intellectual property of their respect
Slide 14: Phase readouts in the next 24 months
Leading AI x Bio platform driving 2 Phase 2 readouts in the next 24 months COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 14 C A T A L Y S T S ABS-201 in AGA o Ph1/2a Study initiated Dec 2025 o Safety, Tolerability, and PK readout expected 1H 2026 o Interim PoC Readout – anticipated 2H 202
Slide 15: Internal Pipeline
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 15 I N T E R N A L P I P E L I N E Absci’s progress in Drug Creation A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia Ph1/2a study initiated Dec 2025 Interim POC readout anticipated
Slide 16: ABS-201 potential new category of therapy in hair re-growth
ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” Significant clinical and commercial unmet need in androgenetic alopecia1. Strong scientific rationale, with validated target, de-risked Mode of Action, and pharmacology2. 3. COPYRIGHT© 2026 ABSCI CORPORATION | A
Slide 17: AGA underserved patient population
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 17 A B S - 2 0 1 A G A Underserved patient population looking for therapeutic innovation ~80 million Americans live with androgenetic alopecia (AGA) FEMALE AGA ~30M women in the U.S. Only 1 FDA approved drug ther
Slide 18: PRLR inhibition for androgenetic alopecia
18 A B S - 2 0 1 | A G A PRLR inhibition for androgenetic alopecia is an innovative alternative to current treatment options P R O P O S E D D I R E C T I M P A C T O F A B S - 2 0 1 O N H A I R C Y C L E S T A G E S Telogen Resting Phase Hair falls out Catagen ↑↑ Apoptosis & Regression 2-4 weeks An
Slide 19: Prolactin impacts on organ-cultured human hair follicles
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 19 A B S - 2 0 1 A G A Prolactin impacts on organ-cultured human hair follicles Prolactin prematurely induces a catagen-like stage in organ-cultured human hair follicles1 characterized by: Vehicle 400 ng/ml prola
Slide 20: PRLR inhibition anticipated to be safe supported by human genetics
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 20 A B S - 2 0 1 A G A PRLR inhibition anticipated to be safe & well tolerated as supported by human genetics I. II. III. NV = Nonvariant ND = Not determined I. II. III. I. II. III. IV. Kobayashi, 2018 NEJM Moriw
Slide 21: Terminal hair count in primate model
21 A B S 2 0 1 | A G A Terminal hair count ”Thick Hairs” in prior bald areas o Hair regrowth observed for both male and female animals (>100 hairs/cm2 increase in bald area at week 28 of treatment*) # T hi ck H ai rs Time (w) 20 0 100 0 25 0 150 50 30 0 4 8 12 16 20 24 A S S E S S M E N T A R E A =
Slide 22: ABS-201 superior efficacy vs topical minoxidil
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 22 A B S - 2 0 1 A G A ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Administration: mAbs i.p. biweekly; Minoxidil topical daily ABS-201 vs minoxidil/untreated/isotype **p<0.0
Slide 23: NHP PK data confirms extended half-life
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 23 A B S - 2 0 1 A G A 56 Day NHP PK data confirms extended half-life profile and high SC bioavailability 0 20 40 60 102 10 3 104 10 5 106 107 Single Dose Comparative PK Profile in NHPs Time (d) m A b se ru m c o
Slide 24: Modelling shows superiority of ABS-201 vs HMI-115
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 24 A B S - 2 0 1 A G A Modelling shows superiority of ABS-201 vs HMI-115 on PK & Receptor Occupancy >3x extended half-life in NHPs predicted to translate in humans to Q8W-Q12W dosing intervals PK profile predicte
Slide 25: ABS-201 human ex vivo culture study
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 25 A B S - 2 0 1 | A G A ABS-201 in human ex vivo culture study supports MOA in human scalp follicles ABS-201 significantly prolongs anagen/inhibits catagen and stimulates hair matrix proliferation Anagen Early Catagen Mid Catagen lgG Ctrl ABS
Slide 26: Additional ABS-201 ex vivo study
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 26 A B S - 2 0 1 | A G A Additional ABS-201 ex vivo study found: o Prolonging anagen phase and blocking catagen, thereby inhibiting telogen effluvium o Protecting and promoting hair follicle stem cells and and restoring CD34+ progenitor cells
Slide 27: Phase 1/2a trial design in AGA
Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in AGA Design Elements: o Double-Blind, Placebo-controlled, FIH o Multi-site study in Australia o Dose range ensures predicted >90% RO Population: o Up to 227 male & female healthy participants o SAD; n= 32 healthy volunt
Slide 28: ABS-201 TPP offers new treatment category in AGA
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 28 A B S - 2 0 1 | A G A ABS-201 TPP aims to offer a new treatment category in AGA based on efficacy and convenience 0 10 20 30 40 50 60 70 80 Ef fic ac y (t er m in al h ai rs /c m 2) Topical Minoxidil Oral Minoxidil FinasteridePRP Transplant
Slide 29: Consumer research validates market potential of ABS-201
Consumer Research Commissioned by Absci Validates Market Potential of ABS-201 Significant Unmet Need: Driven by psycho-social impacts (loss of confidence, self- esteem) from AGA Strong Commercial Demand: Nearly all men and roughly 90% of women are inclined to ask their doctors about ABS-201 High Val
Slide 30: Patient funnel and TAM
5-9M Pts Treated/Year Assuming 2-3 Year Durability Patient Funnel >$25B E S T I M A T E D U . S . T A M >$40B P O T E N T I A L G L O B A L T A M Total AGA pts in the US 50M male, 30M female Income ≥$75K (US Census) Pts 17-69 yo Concerned / motivated about hair loss Strong interest in TPP Strongest
Slide 31: Internal Pipeline
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 31 I N T E R N A L P I P E L I N E Absci’s progress in Drug Creation A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia Ph1/2a study initiated Dec 2025 Interim POC readout anticipated
Slide 32: ABS-201 in Endometriosis addresses unmet medical need
Development of ABS-201 in Endometriosis Addresses Long-standing Unmet Medical Need and Poor standard of care 1. Large, untapped market offers significant upside potential 2. Strong Biological And Clinical Rationale: Including POC for PRLR mechanism in humans 3. COPYRIGHT© 2026 ABSCI CORPORATION | AL
Slide 33: Treatment paradigm for endometriosis
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 33 A B S - 2 0 1 | E N D O M E T R I O S I S Hormonal therapies and surgical intervention make up the treatment paradigm for Endo • Endo is a chronic condition with currently no medical or surgical cure • Roughly
Slide 34: Pain remains a persistent issue in endometriosis
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 34 Pain remains a persistent, chronic issue for women with endometriosis A B S - 2 0 1 E N D O Illustrative Endometrial Patient Journeys First Period Desire to Conceive Perimenopause PMID 40323608, PMID 17498711,
Slide 35: PRLR antagonism novel MoA in Endometriosis
o Endometriotic lesions produce prolactin under estrogen/progesterone control. o Excess prolactin promotes lesion growth and sensitizes pain-sensing nerves, contributing to chronic pelvic pain. o Prolactin signaling is independent of sex-hormone pathways, offering a differentiated, non-hormonal trea
Slide 36: Prolactin receptor localization in human endometrium
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 36 A B S - 2 0 1 E N D O Localization And Temporal Expression Of Prolactin Receptor In Human Endometrium PRL and PRLR increase during secretory phase in healthy tissue, and is overexpressed in endometrium of pati
Slide 37: Prolactin regulates pain responses
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 37 A B S - 2 0 1 E N D O Prolactin Regulates Pain Responses via a Female- Selective Nociceptor-Specific Mechanism PRLR antagonism suppresses postoperative pain in female mice and inhibits endometriosis interna fo
Slide 38: PRLR antagonism reduces lesion formation and pain in mouse model
PRLR antagonism reduces lesion formation and pain in endometriosis mouse model 38 A B S - 2 0 1 | E N D O M E T R I O S I S COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED * 1 2 3 4 5 0 * * *D is ea se S co re Control Graft + danazol + faslodex + cetrorelix Prolactin Antagonist Antibody Prol
Slide 39: ABS-201 differentiated profile targeting large market
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 39 >$4.5B at peak sales Potential to generate A B S - 2 0 1 | E N D O M E T R I O S I S ABS-201: a potentially differentiated profile targeting a large underserved market opportunity NOVEL TREATMENT OPTION FOR ~9M PATIENTS IN THE U.S. ALONE WI
Slide 40: Internal Pipeline
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 40 I N T E R N A L P I P E L I N E Absci’s progress in Drug Creation A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia Ph1/2a study initiated Dec 2025 Interim POC readout anticipated
Slide 41: ABS-101 TL1A
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED ABS-101 | TL1A AI Designed TL1A antibody in Ph1 Clinical development; ready for partnering 2024 20252024 2025 2026 Interim results from the first cohorts of Phase 1 trial demonstrated extended half-life as compar
Slide 42: AI platform generates high affinity variants
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 42 Successful application of AI platform to generate high affinity variants High Affinity mAbs with Preserved Cross- Reactivity A B S - 1 0 1 T L 1 A MK-7240 # RVT-3101 # Epitope bins on TL1A* ABS-101-A Absci AI-
Slide 43: High affinity candidate with potential for superior potency
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 43 AI-designed candidate with high affinity and potential for superior potency A B S - 1 0 1 T L 1 A Affinity by Biolayer Interferometry (BLI) Apoptosis Inhibition Assay in TF-1 Cells 1101001000 1 10 100 1000 Mon
Slide 44: Internalization of mAb:TL1A complexes
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 44 Internalization of mAb:TL1A complexes potentially contribute to immune activation and formation of ADA A B S - 1 0 1 T L 1 A mAb:TL1 Complex Internalization in THP-1 Cells mAb only ABS-101-A RVT-3101#MK-7240#
Slide 45: NHP Pharmacokinetics & CMC Data
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 45 NHP Pharmacokinetics & CMC Data A B S - 1 0 1 T L 1 A PK Profile of Anti-TL1A mAbs 2-3x extended half-life in NHPs over 1st generation clinical competitors ABS-101 shows enhanced biodistribution in NHPs, compa
Slide 46: ABS-101 NHP data
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 46 ABS-101 Non-Human Primate (NHP) data A B S - 1 0 1 T L 1 A Data confirm engagement of soluble TL1A (sTL1A) in non-human primates. Target engagement is dose-dependent with a ceiling effect. ABS-101's extended h
Slide 47: Internal Pipeline
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 47 I N T E R N A L P I P E L I N E Absci’s progress in Drug Creation A B S - 2 0 1 A G A Accelerated development of ABS-201 in androgenetic alopecia Ph1/2a study initiated Dec 2025 Interim POC readout anticipated
Slide 48: Tertiary Lymphoid Structures: focus of Reverse Immunology
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 48 Tertiary Lymphoid Structures (TLS): The focus of Absci’s Reverse Immunology approach T A R G E T D I S C O V E R Y Rapidly growing evidence illustrates correlation between TLS-derived antibodies in the tumor m
Slide 49: Reverse Immunology platform identifies antigens
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 49 Reverse Immunology platform identifies the antigens targeted by endogenous antibodies produced in tumor lymphoid structures (TLS) A B S - 3 0 1 doi: 10.1101/2021.02.06.430058 Samples collected from patients wi
Slide 50: Patient-derived antibody blocks immunosuppressive cytokine
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 50 A patient-derived antibody discovered by reverse immunology blocks an immunosuppressive cytokine A B S - 3 0 1 doi: 10.1101/2021.02.06.430058 ABS-301 Rescues Pro-Inflammatory Signaling Through Inhibition of Im
Slide 51: ABS-301 key findings tumor growth mouse model
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 51 2024 20252024 2025 2026 Key Findings A B S - 3 0 1 Activation of the ABS-301– targeted pro-inflammatory pathway triggers a robust anti- tumor immune response. Study Overview Mouse melanoma cells were genetical
Slide 52: ABS-301 target expression in squamous cell carcinomas
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 52 Expression of ABS-301’s target suggests broad potential in squamous cell carcinomas A B S - 3 0 1 Values shown are log2(TPM+1) normalized. Multiple biopsies from a patient are included in the analysis. REFEREN
Slide 53: Expression in Lung Squamous Cell Carcinoma
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 53 Expression in Lung Squamous Cell Carcinoma (LUSC): no change with treatment and strong negative correlation with CD8+ T cell infiltration A B S - 3 0 1 Pre-treatment Post-treatment A B S- 30 1 t ar ge t e xp r
Slide 54: Preclinical studies in immuno-oncology
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 54 Ongoing preclinical studies exploring broad application in immuno-oncology A B S - 3 0 1 Based on literature and potential competitive molecules, the following indications could be of interest: Indication US P
Slide 55: De novo AI model on HER2 discovers distinct antibodies
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 55 Deploying de novo AI model on HER2 led to discovery of antibodies displaying molecular interactions distinct from trastuzumab A B S - 5 0 1 Zero shot de novo AI discovery on HER2 Hits with edit distance of up
Slide 56: Enhanced ADCC activity compared to trastuzumab
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 56 AI-designed antibodies demonstrate measurable enhancement of ADCC activity compared to trastuzumab A B S - 5 0 1 ADCC Assay Principle #Estimated performance of a putative clinical competition molecule generate
Slide 57: AI-designed antibodies suppress HER2+ breast tumors
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 57 AI-designed antibodies suppress growth of trastuzumab-sensitive & resistant HER2+ breast tumors A B S - 5 0 1 Mouse xenograft model using EFM192A (HER2+ BC; Tz sensitive) Mouse xenograft model using JIMT-1 (HE
Slide 58: AI-designed antibodies address unmet medical need
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 58 AI-designed antibodies create opportunities to address unmet medical need A B S - 5 0 1 Currently exploring breast cancer as opportunity: alternative to or post Enhertu® Later-line treatment regimens for HER2-
Slide 59: Leading AI models create novel therapeutics
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 59 P L A T F O R M Leading AI models to create novel & differentiated therapeutics “Smart” biologics Enhanced Potency & MOA Engineer selectivity, minimizing off target toxicity Agonism vs. Antagonism Bind Specifi
Slide 60: Leadership in AI de novo design
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 60 P L A T F O R M Leadership in AI de novo design of antibody-based therapeutics De Novo Antibody DesignAI Lead Optimization De novo antibody design model creates epitope-specific binders given a target structur
Slide 61: 6-week lab-in-the-loop active learning cycles
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 61 P L A T F O R M Our AI platforms are enabled by our 6-week ‘lab-in-the loop’ active learning cycles Lab-in-the-loopAI Platforms D E N O V O A N T I B O D Y D E S I G N L E A D O P T I M I Z A T I O N AI guided
Slide 62: AbsciDesign AI models for de novo antibody design
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 62 P L A T F O R M AbsciDesign comprises two categories of AI models for de novo antibody design AbsciBindAbsciGen antibody<>antigen complex structure and sequence design Antibody design scoring and filtering Ant
Slide 63: AbsciDesign end-to-end design-validation workflow
The AbsciDesign AI platform delivers de novo antibodies via an end-to-end design-validation workflow COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 63 P L A T F O R M STEP 1. Define design parameters STEP 2. Fine-tune and deploy AbsciGen and AbsciBind to generate hundreds of thousands of va
Slide 64: De novo design of antibody binding Caldera region of HIV-1
64C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . C A S E S T U D Y de novo design of an antibody that binds the Caldera region of HIV-1 trimer
Slide 65: HIV design challenge
65C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . No natural or synthetic antibody for HIV exists today because immune system cannot derive an antibody that is universally neutralizing against HIV Design challenge: create universally neutralizing HIV
Slide 66: HIV-Caldera: Determine inputs and design
66C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: Determine inputs and design D E N O V O D E S I G N HIV Env Trimer Challenge : • Highly glycosylated • Extremely high sequence diversity among isolates • High mutation rate at common neut
Slide 67: Best structures selected from de novo model
67C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . 4 best structures selected from 10,000+ structures generated by de novo model D E N O V O D E S I G N 17b Structure S1 HCDR3 Structure S3 HCDR3 Structure S2 HCDR3 Structure S4 HCDR3 HeavyLight
Slide 68: Molecular dynamics simulation of de novo antibodies
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 68 2024 20252024 2025 2026 Applied molecular dynamics simulation to de novo designed antibodies C A S E S T U D Y # 1
Slide 69: Enriched de novo library binds open Env trimer
69C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . H A ta g Antigen Clade A Env trimer Closed Open Enriched de novo library binds open, not closed, Env trimer conformation in YSD D E N O V O D E S I G N Closed Open Clade B Env trimer
Slide 70: SPR data consistent with caldera binding
70C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . SPR data demonstrate binding characteristics consistent with binding of caldera D E N O V O D E S I G N
Slide 71: SPR shows no binding to GP120 monomer
71C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: SPR demonstrates no binding of de novo designs to GP120 monomer D E N O V O D E S I G N Hypothesis: If the designed mAbs are binding to the caldera region we should not observe binding to
Slide 72: HIV-Caldera summary
72C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . HIV-Caldera: demonstrating AI de novo design for challenging target H I V D E N O V O D E S I G N SUMMARY de novo design model created a novel and diverse antibody which binds multiple clades of HIV i
Slide 73: AI Optimization for pH sensitivity
73C O P Y R I G H T © 2 0 2 5 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . CASE STUDY A I O p t i m i z a t i o n f o r p H s e n s i t i v i t y
Slide 74: AI lead optimization platform for smart biologics
AI lead optimization platform for ‘smart biologics’ COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 74 C A S E S T U D Y # 2 The Challenge The diversity of antibodies is vast, making it impossible for traditional methods to explore effectively. Absci Solution Our AI can search a space of ~10
Slide 75: pH sensitivity may reduce toxicity or improve efficacy
pH sensitivity may reduce toxicity and/or improve efficacy of therapeutic mAbs COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 75 C A S E S T U D Y # 2 Tumor specificity improves efficacy and reduces ”on-target off-tumor” toxicities Binding occurs in the acidic pH of the tumor microenvironme
Slide 76: Models identify pH sensitive Fab variants
Models identify pH sensitive Fab variants from the same lead for either indication COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 76 C A S E S T U D Y # 2 1. Library for model training sampled 60 positions on heavy chain framework and CDRs with up to 7 substitutions biased for ionizable res
Slide 77: Hits reformatted as mAbs show desired binding
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 2024 20252024 2025 2026 Hits reformatted as mAbs show desired binding profiles SUMMARY AI optimized leads achieves variants with pH sensitive binding up to 100x differential pH-sensitive leads had no liabilities
Slide 78: Summarized platform case studies
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 78 Summarized platform case studies C A S E S T U D I E S De Novo Design de novo design model created molecule binds multiple clades of HIV suggesting successful targeting of the caldera epitope Represents second
Slide 79: Generative AI Re(Generative) Biology
Generative AI Re(Generative) Biology A B S C I C O R P O R A T I O N 2 0 2 6 A L L R I G H T S R E S E R V E D